Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease.
Therap Adv Gastroenterol
; 11: 1756284818759930, 2018.
Article
in En
| MEDLINE
| ID: mdl-29623105
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Therap Adv Gastroenterol
Year:
2018
Document type:
Article
Affiliation country:
Noruega
Country of publication:
Reino Unido